Skip to main content
. Author manuscript; available in PMC: 2020 May 1.
Published in final edited form as: Mol Cancer Ther. 2019 Sep 5;18(11):1916–1925. doi: 10.1158/1535-7163.MCT-18-1334

Figure 5: In vivo antitumor activity of RX-5902 in TNBC PDX models.

Figure 5:

The effect of RX-5902 was evaluated against 3 TNBC PDX models. Mice were randomized to treatment with vehicle or RX-5902 60mg/kg once daily 5 days on 2 days off. This dose was selected based on the PK data in Figure 4D-E. (A) CU_TNBC_002 (TGI 47.97%, p<0.05), (B) CU_TNBC_004 (TGI: 84.14%, p<0.0001) and (C) CU-TNBC_014 (TGI 82.49%, p<0.0001).